Publications by authors named "W Quintilio"
SARS-CoV-2 Rapid Antigen Test Based on a New Anti-Nucleocapsid Protein Monoclonal Antibody: Development and Real-Time Validation.
Microorganisms
September 2023
SARS-CoV-2 diagnostic tests have become an important tool for pandemic control. Among the alternatives for COVID-19 diagnosis, antigen rapid diagnostic tests (Ag-RDT) are very convenient and widely used. However, as SARS-CoV-2 variants may continuously emerge, the replacement of tests and reagents may be required to maintain the sensitivity of Ag-RDTs.
View Article and Find Full Text PDFDisadvantages of using murine monoclonal antibodies (mAb) in human therapy, such as immunogenicity response, led to the development of technologies to transform murine antibodies into human antibodies. The murine anti-FGF2 3F12E7 mAb was proposed as a promising agent to treat metastatic melanoma tumors; once it blocks the FGF2, responsible for playing a role in tumor growth, angiogenesis, and metastasis. Considering the therapeutic potential of anti-FGF2 3F12E7 mAb and its limited use in humans due to its origin, we used this antibody as the template for a guided selection humanization technique to obtain human anti-FGF2 mAbs.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers used predictive tools to create a heatmap identifying which amino acid changes could lower the binding affinity of the antibody's peptides to HLA II molecules without affecting the antibody's ability to target its specific antigen.
- * By applying this method to adalimumab, an antibody used for treating inflammatory conditions, the study produced 200 variants with reduced HLA binding scores and identified three that had improved affinity and neutralization capabilities compared to the original adalimumab.
Article Synopsis
- Tetanus toxin (TeNT) is created by a widespread spore-forming bacillus, and although there's a safe vaccine, tetanus remains common in low-income countries due to insufficient booster shots and varying vaccine responses.* -
- Researchers identified a set of monoclonal antibodies (mAbs) that can neutralize TeNT by preventing its binding to neurons and showed that a combination of three specific mAbs can protect mice from the toxin's effects.* -
- They developed stable cell lines to produce large quantities of these mAbs and conducted various tests (like ELISA and surface plasmon resonance) to confirm the antibodies' effectiveness in binding to TeNT and inhibiting its activity.*
Hemolytic Uremic Syndrome (HUS) associated with Shiga-toxigenic (STEC) infections is the principal cause of acute renal injury in pediatric age groups. Shiga toxin type 2 (Stx2) has in vitro cytotoxic effects on kidney cells, including human glomerular endothelial (HGEC) and Vero cells. Neither a licensed vaccine nor effective therapy for HUS is available for humans.
View Article and Find Full Text PDF